Entity

Time filter

Source Type


This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.


Patent
Aventis Pharmaceuticals | Date: 2012-04-18

The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R


This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.


Patent
Aventis Pharmaceuticals | Date: 2011-06-10

The present invention is directed to nuclear factor B (NFB)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NFB. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NFB induction in a patient, methods and compositions for lowering NFB induction in a patient, methods for inhibiting inflammation, and methods for manufacutre of a medicament intended for the treatment and/or prevention of an NFB-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.


Patent
Aventis Pharmaceuticals | Date: 2012-04-24

The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, R

Discover hidden collaborations